Dova Pharmaceuticals, Inc. announced the appointment of Mark W. Hahn as the company’s Chief Financial Officer. A veteran Chief Financial Officer of the biotech industry, Mr. Hahn previously served as the Chief Financial officer of Cempra, Inc. from 2010 until it was acquired by Melinta Therapeutics, Inc. in November 2017. Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018. Doug Blankenship, Dova’s previous Chief Financial Officer, has agreed to step down.